Page 41 - index

La prevenzione del tromboembolismo

27 Degli Esposti L, Sangiorgi D, Di Pasquale G, et al. temic embolism in people with atrial fbrillation.
Adherence to treatment and anticoagulation con- NICE technology appraisal guidance 256 - 2012.
trol in vitamin K antagonist-treated patients: an 36 Meretoja A, Kaste M, Roine RO, et al. Direct costs
administrative database analysis in a large Italian of patients with stroke can be continuously moni-
population. Farmacoeconomia e percorsi terapeu- tored on a National level: performance, effective-
tici 2011;12:69-75. ness, and costs of treatment episodes in stroke
28 Gallagher AM, Setakis E, Plumb JM, et al. Risks (PERFECT stroke) database in Finland. Stroke
of stroke and mortality associated with suboptimal 2011;42:2007-12.
anticoagulation in atrial fbrillation patients. Thromb 37 Colonna P, Abrignani MG, Colivicchi F, et al. Docu-
Haemost 2011;106:968-77. mento ANMCO su prevenzione del tromboemboli-
29 Fuster V, Chinitz JS. Net clinical beneft of warfarin: smo nella fbrillazione atriale e ruolo dei nuovi anti-
extending the reach of antithrombotic therapy for coagulanti orali. G Ital Cardiol 2013;14:295-322.
atrial fbrillation. Circulation 2012;125:2285-7. 38 Eerenberg ES, Kamphuisen PW, Sijpkens MK,
30 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabiga- et al. Reversal of rivaroxaban and dabigatran by
tran vs. warfarin in patients with atrial fbrillation. N prothrombin complex concentrate: a randomized,
Engl J Med 2009;361:1139-51. placebo-controlled, crossover study in healthy sub-
31 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban jects. Circulation 2011;124:1573-9.
vs. warfarin in nonvalvular atrial fbrillation. N Engl J 39 Healey JS, Eikelboom J, Douketis J, et al. Peripro-
Med 2011;364:806-17. cedural bleeding and thromboembolic events with
32 Granger CB, Alexander JH, McMurray JJ, et al. dabigatran compared with warfarin: results from
Apixaban vs. warfarin in patients with atrial fbrilla- the Randomized Evaluation of Long-Term Antico-
tion. N Engl J Med 2011;365:981-92. agulation Therapy (RE-LY) randomized trial. Circula-
33 Dentali F, Riva N, Crowther M, et al. Effcacy and tion 2012;126:343-8.
safety of the novel oral anticoagulants in atrial fbril- 40 Ruppar MT, Conn VS, Russell CL. Medication ad-
lation. A systematic review and meta-analysis of the herence interventions for older adults: literature re-
literature. Circulation 2012;126:2381-91. view. Res Theory Nurs Pract 2008;22:114-47.
34 Dabigatran etexilate for the prevention of stroke 41 Schulman S, Schortt B, Robinson M, et al. Adher-
and systemic embolism in atrial fbrillation. NICE ence to anticoagulant treatment with dabigatran in
technology appraisal guidance 249 - 2012. a real-work setting. J Thromb Haemost 2013; ‘Ac-
35 Rivaroxaban for the prevention of stroke and sys- cepted Article’ doi: 10.1111/jth. 122411.

39